Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M

LIFECORE BIOMEDICAL, INC. DE

Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.
Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.
Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.
Signed five new programs during transition, including two commercial site transfer programs in Q4.
Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE reported the transition period ended December 31, 2025 results: revenue $75.5 Million, net income $18.0 million.

Period: the transition period ended December 31, 2025
Revenue: $75.5 Million
Net income: $18.0 million
Result: reported results

Exact text from the filing

Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- --

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE reported the fourth quarter ended December 31, 2025 results: revenue $35.7 Million.

Period: the fourth quarter ended December 31, 2025
Revenue: $35.7 Million
Result: reported results

Exact text from the filing

Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.